Results of the pilot study for the Hypertension in the Very Elderly Trial

被引:219
作者
Bulpitt, CJ
Beckett, NS
Cooke, J
Dumitrascu, DL
Gil-Extremera, B
Nachev, C
Nunes, M
Peters, R
Staessen, JA
Thijs, L
机构
[1] Univ London Imperial Coll Sci Technol & Med, Fac Med, London W12 0NN, England
[2] Univ Med & Pharm, Cluj Napoca, Romania
[3] Univ Granada, Granada, Spain
[4] St Anna Hosp, Sofia 1784, Bulgaria
[5] Katholieke Univ Leuven, Dept Mol & Cardiovasc Res, Louvain, Belgium
关键词
hypertension; very elderly; diuretics; angiotensin-converting enzyme inhibitors; stroke;
D O I
10.1097/00004872-200312000-00030
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Background The risks and benefits of treating hypertension in individuals older than 80 years are uncertain. A meta-analysis has suggested that a reduction in stroke events of 36% may have to be balanced against a 14% increase in total mortality. Objectives To report the results of the pilot study of the Hypertension in the Very Elderly Trial (HYVET), which is in progress to address these issues. Methods The HYVET-Pilot was a multicentre international open pilot trial. In 10 European countries, 1283 patients older than 80 years and with a sustained blood pressure of 160-219/90-109 mmHg were allocated randomly to one of three treatments: a diuretic-based regimen (usually bendroflumethiazide; n = 426), an angiotensin-converting enzyme inhibitor regimen (usually lisinopril; n = 431) or no treatment (n = 426). The procedure permitted doses of the drug to be titrated and diltiazem slow-release to be added to active treatment Target blood pressure was < 150/80 mmHg and mean follow-up was 13 months. Results In the combined actively treated groups, the reduction in stroke events relative hazard rate (RHR) was 0.47 [95% confidence interval (Cl) 0.24 to 0.93] and the reduction in stroke mortality RHR was 0.57 (95% Cl 0.25 to 1.32). However, the estimate of total mortality supported the possibility of excess deaths with active treatment (RHR 1.23, 95% Cl 0.75 to 2.01). Conclusions The preliminary results support the need for the continuing main HYVET trial. It is possible that treatment of 1000 patients for 1 year may reduce stroke events by 19 (nine non-fatal), but may be associated with 20 extra non-stroke deaths. (c) 2003 Lippincott Williams & Wilkins.
引用
收藏
页码:2409 / 2417
页数:9
相关论文
共 12 条
  • [1] Hypertension in the Very Elderly Trial (HYVET) - Protocol for the Main Trial
    Bulpitt, C
    Fletcher, A
    Beckett, N
    Coope, J
    Gil-Extremera, B
    Forette, F
    Nachev, C
    Potter, J
    Sever, P
    Staessen, J
    Swift, C
    Tuomilehto, J
    [J]. DRUGS & AGING, 2001, 18 (03) : 151 - 164
  • [2] THE HYPERTENSION IN THE VERY ELDERLY TRIAL (HYVET) - RATIONALE, METHODOLOGY AND COMPARISON WITH PREVIOUS TRIALS
    BULPITT, CJ
    FLETCHER, AE
    AMERY, A
    COOPE, J
    EVANS, JG
    LIGHTOWLERS, S
    OMALLEY, K
    PALMER, A
    POTTER, J
    SEVEV, P
    STAESSEN, J
    SWIFT, C
    [J]. DRUGS & AGING, 1994, 5 (03) : 171 - 183
  • [3] PROGNOSTIC-SIGNIFICANCE OF BLOOD-PRESSURE IN THE VERY OLD - IMPLICATIONS FOR THE TREATMENT DECISION
    BULPITT, CJ
    FLETCHER, AE
    [J]. DRUGS & AGING, 1994, 5 (03) : 184 - 191
  • [4] COX DR, 1972, J R STAT SOC B, V34, P187
  • [5] CANCER MORTALITY AND ATENOLOL TREATMENT
    FLETCHER, AE
    BEEVERS, DG
    BULPITT, CJ
    COLES, EC
    DOLLERY, CT
    LEDINGHAM, JG
    PALMER, AJ
    PETRIE, JC
    WEBSTER, J
    [J]. BRITISH MEDICAL JOURNAL, 1993, 306 (6878) : 622 - 623
  • [6] Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials
    Gueyffier, F
    Bulpitt, C
    Boissel, JP
    Schron, E
    Ekbom, T
    Fagard, R
    Casiglia, E
    Kerlikowske, A
    Coope, J
    [J]. LANCET, 1999, 353 (9155) : 793 - 796
  • [7] FINAL REPORT ON THE ASPIRIN COMPONENT OF THE ONGOING PHYSICIANS HEALTH STUDY
    HENNEKENS, CH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (03) : 129 - 135
  • [8] HODKINSON H M, 1972, Age and Ageing, V1, P233, DOI 10.1093/ageing/1.4.233
  • [9] Change in blood pressure in the age interval 70-90. Late blood pressure peak related to longer survival
    Lernfelt, B
    Svanborg, A
    [J]. BLOOD PRESSURE, 2002, 11 (04) : 206 - 212
  • [10] MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163